2024-01-26 Grand Pharma’s Milestone in the Layout of Structural Heart Field, the Establishment of Shanghai R&D Center

2024-01-26 The IND Application in China of Grand Pharma’s Global Innovative Therapeutic Tumor Vaccine ARC01 Was Approved

2024-01-24 Grand Pharma Strategically Controls Duoputai Pharmaceutical Technology, Strengthening the Strategic Plan in Field of Cerebro-cardiovascular Disease Treatment

2024-01-24 Prof. Jingquan Zhong’s Team at Qilu Hospital Successfully Performs HeartLight X3 Balloon Laser Ablation Surgery

2024-01-24 The IND of GPN00884, a global innovative ophthalmic preparation of Grand Pharma approved by the National Medical Products Administration of China

2024-01-24 Grand Pharma’s Core Neurointerventional Products Presented at the Annual of Chinese Interventional Neuroradiolcy Society of CSA

2024-01-22 Grand Pharma’s Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Has Submitted BLA Application to US FDA

2024-01-19 Grand Pharma Strategically Acquires Tianjin Tanabe

2024-01-19 Grand Pharma’s Coronary Imaging Device for Intracavity Diagnosis NOVASIGHT Achieves First Clinical Application

2024-01-19 The Phase II Clinical Study of Grand Pharma’s Global Innovative Product STC3141 Has Completed the First Patient Enrollment and Dosing in China

2023-11-21 The Launch of “the Liver Cancer Assistance Yttrium Little Red Flower Health Fund Project”: Low-income Patients Eligible for Financial Assistance

2023-11-16 Bi-Monthly Progress Snapshot of Grand Pharma (September-October)